Cipla Ltd.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that the United States Food and Drug Administration (USFDA) has classified the inspection conducted at its Goa manufacturing facility from 16-27 September 2019 as Official Action Indicated (OAI). The Company does not believe that this will have any material impact on the US business at this stage. The Company has a strong track record of maintaining the highest standard of compliance and will work closely with the agency to comprehensively address the observations received.

The above information is a part of company’s filings submitted to BSE.